← Search & browse all drugs
BLOOD AND BLOOD FORMING ORGANS › ANTITHROMBOTIC AGENTS › ANTITHROMBOTIC AGENTS › Platelet aggregation inhibitors excl. heparin
triflusal
B01AC18
Adult Dosing
- Prevention of thromboembolic events: 600 mg daily administered in two divided doses of 300 mg
- Acute myocardial infarction: 300 mg to 600 mg daily
Pediatric Dosing
- Safety and efficacy in pediatric patients have not been established
Indications
- Prevention of ischemic stroke and secondary prevention of myocardial infarction
- Treatment and prevention of thromboembolic complications in vascular disorders
Mechanism of Action
- Platelet aggregation inhibitor structurally related to aspirin
- Irreversibly inhibits platelet cyclooxygenase (COX-1), decreasing thromboxane A2 synthesis
- Inhibits platelet cyclic nucleotide phosphodiesterase, increasing intracellular cAMP levels
Contraindications
- Hypersensitivity to triflusal, salicylates, or excipients
- Active pathological bleeding such as peptic ulcer or intracranial hemorrhage
- Severe hepatic impairment
- History of asthma or allergic reactions precipitated by salicylates
Adverse Reactions
- Dyspepsia and gastrointestinal discomfort
- Epigastric pain, nausea, and vomiting
- Increased risk of bleeding and bruising
- Headache and dizziness
- Insomnia
Drug Interactions
- Anticoagulants (e.g., warfarin) and other antiplatelet agents: increased risk of hemorrhage
- Nonsteroidal anti-inflammatory drugs (NSAIDs): synergistic gastrointestinal toxicity and bleeding risk
- Corticosteroids: increased risk of gastrointestinal ulceration
- Oral hypoglycemic agents: potential enhancement of hypoglycemic effects
Curated Content: Needs Vetting Before Put to Clinical Use